You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 44 No. 1, January 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Systemic {alpha}-Interferon in Multiple Sclerosis

Long-term Patient Follow-up

Hillel S. Panitch, MD

Arch Neurol. 1987;44(1):61-63.


Abstract

• Twelve patients with relapsing multiple sclerosis who had participated in a clinical trial of systemic (subcutaneous) natural {alpha}-interferon were interviewed and reexamined 4.3 years after beginning interferon treatment and 2.3 years after completion of the study. There was a progressive reduction in exacerbation rate from 1.33 per year to 0.47 per year. Overall neurologic function and disability did not change significantly. Six patients stabilized or improved, and were able to carry on normal daily activities. There were no long-term deleterious side effects. These results are similar to those described for patients treated with intrathecal β-interferon. The mechanism of the prolonged beneficial effect is unknown, but is unlikely to represent antiviral activity in the central nervous system, and more probably involves systemic immunoregulatory functions. The systemic route of administration of interferon may be as effective as the intrathecal route in multiple sclerosis, and is potentially less hazardous.



Author Affiliations

From the Department of Neurology, University of Maryland, Baltimore.


Footnotes

Accepted for publication Sept 2, 1986.

Reprint requests to Department of Neurology, University of Maryland, 22 S Greene St, Baltimore, MD 21201 (Dr Panitch).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
Jacobs and Johnson
Arch Neurol 1994;51:1245-1252.
ABSTRACT  

Exacerbation of Multiple Sclerosis After the Administration of Recombinant Human Interferon Alfa
Larrey et al.
JAMA 1989;261:2065-2065.
ABSTRACT  

Systemic Interferon Alfa in Multiple Sclerosis
Weinshenker and Ebers
Arch Neurol 1989;46:251-252.
ABSTRACT  

Systemic Interferon Alfa in Multiple Sclerosis-Reply
Panitch
Arch Neurol 1989;46:252-252.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.